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Adoptive cell therapy (ACT) with expanded autologous
tumor infiltrating lymphocytes (TIL) has emerged to be a
powerful salvage therapy for metastatic melanoma with
response rates up to 50%. However, the generation of the
TIL ACT product is technically challenging with current
methods requiring a large excess of allogeneic normal
donor (pool) or patient-derived PBMC (200:1 ratio to the
TIL) used as “feeders” to support a rapid expansion
protocol (REP) to generate the final TIL infusion product.
Because PBMC feeder products consist of a heterogenous
cell population, it introduces undesired variability in TIL
expansion rates and phenotype, especially in the yield of
CD8+ T cells that are the most active component of the
TIL product. Here, we have developed an alternative to
PBMC feeders using a K562-based artificial antigen-
presenting cell (aAPC) system expressing CD64, CD86,
and 4-1BBL that is much more practical and cost-
effective. Using PBMC feeders as controls, we found an
optimal aAPC:TIL ratio (50:1) supporting maximal TIL
expansion used for subsequent experiments. Analysis of
the resulting TIL products from multiple experiments
revealed that the aAPC induced higher rates of CD8+
T cell expansion with a comparable effector-memory
phenotype as TIL expanded with the traditional PBMC
feeder approach. The exceptions were CD56 that was
more highly expressed on the CD8+ cells and CD28
which had a lower expression. Notably, TIL expanded
with aAPC were enriched in CD8+ BTLA+ T cells, a
subset highly correlated with clinical response to ACT.
TCR Vab clonotype analysis also found that TIL expan-
sion with the aAPC did not alter the diversity of the
T cell repertoire. Further analysis using gene chip profil-
ing revealed significant differences in gene expression in
TIL products expanded using the aAPC versus with
PBMC feeders. These included an up-regulation of
certain genes in the Wnt pathway, cyclic nucleotide
metabolism, and multiple genes in different stem cell
pathways. This more stem-like profile may have benefi-
cial properties following adoptive transfer. Finally, we
found that CD8+ TIL expanded with aAPC had a similar
anti-tumor effector cell activity in CTL and IFN-g release
assays. Overall, our data demonstrates that this aAPC
system is a suitable alternative to generate clinical-grade
melanoma TIL infusion products for ACT that produces
comparable and perhaps even more active T cells than
current methods. Our group is currently phasing in the
use of these aAPC for our GMP TIL production.
Authors’ details
1Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX,
USA. 2Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA.
3Pediatrics Research, MD Anderson Cancer Center, Houston, TX, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P8
Cite this article as: Forget et al.: Genetically modified artificial antigen-
presenting cells (aAPC) for expansion of melanoma tumor infiltrating
lymphocytes with optimal properties for adoptive cell therapy. Journal
for ImmunoTherapy of Cancer 2013 1(Suppl 1):P8.
1Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX,
USA
Full list of author information is available at the end of the article
Forget et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P8
http://www.immunotherapyofcancer.org/content/1/S1/P8
© 2013 Forget et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
